
- Why Does Crystal Crop Protection Have Growth Potential?
- How Strong Are Crystal Crop Protection's Financials?
- What Are the Biggest Risks in Crystal Crop Protection IPO?
- Is Crystal Crop Protection IPO Valuation Justified at ₹272?
- Author's Take
Crystal Crop Protection's ₹455.49 crore IPO opens on November 18, 2026, with a price band of ₹259–₹272 per share. The company has delivered strong growth, with FY26 revenue rising 17.15% to ₹3,151.97 crore and EBITDA increasing 44.70% to ₹456.23 crore. However, at the upper price band, its post-issue valuation of approximately 30.63x FY26 earnings raises an important question: can its improving profitability justify a premium valuation despite high working capital requirements and debt?
Why Does Crystal Crop Protection Have Growth Potential?
Crystal Crop Protection operates in India's agricultural inputs market, selling crop protection products and hybrid seeds. Its portfolio includes established brands such as Bavistin, Tilt and Proclaim, supported by 14,717 distributors across 23 states and four union territories. This network helps the company reach farmers across different agricultural regions and reduces its dependence on any single market.
The company has also completed 13 business and brand acquisitions, helping it expand without developing every product from scratch. Its research capabilities include 18 granted Indian patents, of which 14 have been commercialised. Products developed internally generated gross margins of 53% in FY26, showing how its own product development can support profitability. Meanwhile, branded sales grew 18.51%, indicating continued demand for its product portfolio.
How Strong Are Crystal Crop Protection's Financials?
Crystal Crop Protection's revenue increased from ₹2,229.93 crore in FY24 to ₹3,151.97 crore in FY26, representing an 18.89% CAGR, the highest among its five listed peers in the IPO comparison. More importantly, EBITDA grew from ₹209.06 crore to ₹456.23 crore, while operating margins improved from 9.38% to 14.47%. This suggests the company has become more profitable as its business has expanded.
Net profit increased from ₹87.24 crore in FY24 to ₹144.91 crore in FY26, while return on capital employed improved from 10.39% to 16.06%. However, cash generation presents a mixed picture. Operating cash flow declined from ₹383.03 crore in FY25 to ₹256.42 crore in FY26, while inventory increased from ₹744.76 crore in FY24 to ₹1,379.07 crore in FY26. This indicates that a substantial amount of capital remains tied up in stock, even as reported profits improve.
What Are the Biggest Risks in Crystal Crop Protection IPO?
Crystal Crop Protection remains heavily dependent on Indian agriculture, with 95.38% of FY26 revenue coming from the domestic market. This exposes the business to monsoon conditions and seasonal farming demand. Raw materials accounted for 68.95% of total expenses, while Chinese suppliers contributed 41.82% of material costs, making profitability sensitive to supply disruptions and changes in chemical prices.
Debt and working capital are equally important concerns. The company had fund-based borrowings of ₹962.67 crore as of August 31, 2026. Although ₹270 crore of IPO proceeds is earmarked for repaying borrowings at the company and its subsidiary, significant financial obligations will remain. Additionally, proceedings involving alleged export duty refund violations of ₹75.53 crore and 305 cheque-bouncing cases involving ₹68.79 crore create legal and payment-recovery uncertainties.
Is Crystal Crop Protection IPO Valuation Justified at ₹272?
At the upper IPO price of ₹272, Crystal Crop Protection's estimated post-issue market capitalisation is approximately ₹4,438 crore, translating into 30.63x FY26 net profit. This is higher than Bayer CropScience's 22.73x, Rallis India's 19.93x and Dhanuka Agritech's 14.38x, while remaining slightly below Sumitomo Chemical India's 31.20x.
The premium valuation is partly supported by Crystal's 18.89% revenue CAGR and improving operating margins. However, its FY26 net profit margin of 4.56% and ROE of 7.94% are the lowest among the five listed peers. Sumitomo Chemical India, despite trading at a similar valuation, reported a 16.04% PAT margin and 17.30% ROE, with no net debt in the comparison. These differences suggest that Crystal's higher growth comes with weaker profitability and greater balance-sheet risk.
The valuation therefore leaves limited room for weaker earnings or slower growth. Crystal will need to demonstrate that its faster revenue expansion can translate into stronger net margins, better cash generation and improved returns on shareholders' capital to support its pricing over time.
Author's Take
Crystal Crop Protection has demonstrated an ability to grow faster than its listed peers while improving operating profitability. Its established brands, distribution network and research capabilities provide a foundation for continued business expansion. The proposed debt repayment could also reduce interest expenses and strengthen its financial position.
However, the biggest concern is the price investors are paying for that growth. At 30.63x FY26 earnings, the valuation is demanding for a company generating a 4.56% net profit margin, with substantial working capital requirements and comparatively low ROE. Strong revenue growth alone may not be enough to justify this premium.
For investors evaluating the IPO, the key factors to monitor are whether EBITDA margin improvements translate into higher net profits, whether inventory and borrowing requirements reduce and whether operating cash flow keeps pace with earnings. Until these improve together, the company's growth prospects need to be weighed carefully against its valuation and financial risks.
For more open and upcoming IPOs, visit INDmoney’s IPO tracker.